Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?

Group 1 - ANI Pharmaceuticals is part of the Medical sector, which includes 1010 companies and is currently ranked 2 in the Zacks Sector Rank [2] - The Zacks Rank system indicates that ANI Pharmaceuticals has a Zacks Rank of 2 (Buy), suggesting a favorable outlook for the stock [3] - Over the past 90 days, the Zacks Consensus Estimate for ANI Pharmaceuticals' full-year earnings has increased by 0.1%, indicating improved analyst sentiment [4] Group 2 - Year-to-date, ANI Pharmaceuticals has returned approximately 6.6%, outperforming the Medical sector average return of 4.4% [4] - ANI Pharmaceuticals is categorized under the Medical - Biomedical and Genetics industry, which consists of 510 companies and is currently ranked 69 in the Zacks Industry Rank [6] - Stocks in the Medical - Biomedical and Genetics industry have gained about 12.6% year-to-date, indicating that ANI Pharmaceuticals is slightly underperforming its industry [6] Group 3 - Another notable stock in the Medical sector is Doximity, which has returned 44.4% year-to-date and has a Zacks Rank of 1 (Strong Buy) [5] - Doximity belongs to the Medical Services industry, which has 59 stocks and is currently ranked 142, with an industry return of +4.3% year-to-date [7]